☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
relapsing forms
Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021
October 13, 2021
BMS' Zeposia (ozanimod) Receives the US FDA's Approval as New Oral Treatment for Relapsing Forms of Multiple Sclerosis
March 27, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.